Skip to content


Bosulif (bosutinib) is a small molecule pharmaceutical. Bosutinib was first approved as Bosulif on 2012-09-04. It is used to treat bcr-abl positive chronic myelogenous leukemia in the USA. It has been approved in Europe to treat myeloid leukemia. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target activated CDC42 kinase 1, tyrosine-protein kinase Fyn, tyrosine-protein kinase TXK, serine/threonine-protein kinase 24, serine/threonine-protein kinase 10, tyrosine-protein kinase FRK, serine/threonine-protein kinase 4, tyrosine-protein kinase Lyn, calcium/calmodulin-dependent protein kinase type II subunit gamma, calcium/calmodulin-dependent protein kinase type 1D, mitogen-activated protein kinase kinase kinase kinase 5, proto-oncogene tyrosine-protein kinase Src, probable serine/threonine-protein kinase SIK1B, serine/threonine-protein kinase SIK2, and serine/threonine-protein kinase SIK3. Bosulif's patents are valid until 2026-11-23 (FDA).
Trade Name Bosulif
Common Name Bosutinib
Indication bcr-abl positive chronic myelogenous leukemia, myeloid leukemia
Drug Class Tyrosine kinase inhibitors
Get full access now